Perspective Therapeutics (NYSE: CATX) spotlights 212Pb radiopharmaceutical cancer pipeline

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Perspective Therapeutics filed a Form 8-K to note that it has updated its corporate presentation, which is attached as Exhibit 99.1. The presentation highlights its focus on next-generation radiopharmaceuticals built on a proprietary lead-212 (212Pb) radioligand platform designed to optimize the therapeutic index and targeted tumor delivery.

The company outlines a wholly owned 212Pb-based oncology portfolio, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma targeting MC1R, and PSV359 targeting FAP-α in solid tumors. Early Phase 1/2a trials are described as showing anti-tumor activity and favorable tolerability, with Phase 1/2 data expected across all three programs in 2026.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Clinical programs with upcoming data: 3 programs Lead isotope: 212Pb Patients in creatinine follow-up: 56 patients

3 metrics

Clinical programs with upcoming data 3 programs Phase 1/2 data expected across all three clinical programs in 2026

Lead isotope 212Pb Described as an optimal isotope for next-generation radiopharmaceutical therapies

Patients in creatinine follow-up 56 patients Blood creatinine during follow-up for all patients treated (n=56)

Key Terms

radiopharmaceuticals, radioligand platform, 212Pb, SSTR2+ neuroendocrine tumors, +2 more

6 terms

radiopharmaceuticals medical

"Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals"

Radiopharmaceuticals are medicines that carry tiny amounts of radioactive material to help doctors see or treat disease inside the body, acting like a tracer dye for imaging or a microscopic guided missile for targeted therapy. They matter to investors because their safety, regulatory approval, production complexity, short shelf life and hospital reimbursement determine how quickly they can reach patients and generate revenue, affecting a company’s sales potential and risk profile.

radioligand platform medical

"Proprietary Radioligand Platform Optimizes Therapeutic Index"

212Pb medical

"Lead-212: Optimal Isotope with Advantages Over Beta and Other Alpha Emitters"

212Pb is a radioactive form of the metal lead used as a delivery vehicle in certain cancer treatments; it decays to produce short-range, high-energy particles that can destroy tumor cells near where it lodges. For investors, it matters because drugs using 212Pb combine scientific promise with regulatory, manufacturing and safety challenges—similar to a precision-guided tool that can be powerful but costly and complex to develop and commercialize.

SSTR2+ neuroendocrine tumors medical

"SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need"

MC1R medical

"VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma"

MC1R is a human gene that encodes a protein on cell surfaces involved in skin and hair pigmentation and in cellular responses to ultraviolet light. For investors, changes or mutations in MC1R matter because they can influence disease risk (notably certain skin cancers), be used as biomarkers, or serve as targets for diagnostics and therapies—think of it as a control switch that drug developers or diagnostic companies might aim to measure or modify.

FAP-ɑ medical

"FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential"

Understanding 8-K Material Events →

04/01/2026 - 04:16 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): April 01, 2026

    

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington		98121
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (206) 676-0900

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	CATX	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On April 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description
99.1		Corporate Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			PERSPECTIVE THERAPEUTICS, INC.

Date:	April 1, 2026	By:	/s/ Joel Sendek
			Joel Sendek Chief Financial Officer

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

Proprietary Radioligand Platform Optimizes Therapeutic Index

Proprietary Pb-Based Chelator Designed for Broader and Safer Use

Lead-212: Optimal Isotope with Advantages Over Beta and Other Alpha Emitters

Imaging Optimizes Targeted Delivery to Tumor

Solid Tumors are an Attractive Market for Radiopharmaceuticals

End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway

Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

Compelling Anti-tumor Activity with Sustained or Deepening Responses

VMT-⍺-NET: Durable Disease Control Across All Doses

Best-in-class Safety Profile1

VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 2 Patients)

VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

Phase 1/2 Data Expected Across All 3 Clinical Programs in 2026

Abbreviations

APPENDIX

NETs Trials

VMT-⍺-NET: Baseline Patient Characteristics in ASCO-GI 2026 Data Analysis

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO-GI 2026 Data Analysis

VMT-⍺-NET: Durable Disease Control Across All Doses

VMT-⍺-NET: Signal of Sustained Anti-tumor Activity

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

Blood Creatinine During Follow-up for All Patients Treated (n=56)

Refractory Metastatic Melanoma Trials

ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

Daily production at regional sites ensures supply of ready-to-administer product

Perspective’s proprietary chelator has been optimized for lead-based RPTs

Construct designed for better clinical outcome

Source: View Original Filing on SEC EDGAR

FAQ

What did Perspective Therapeutics (CATX) disclose in its latest Form 8-K?

Perspective Therapeutics reported that it updated its corporate presentation and filed it as Exhibit 99.1. The presentation outlines its radiopharmaceutical strategy, 212Pb-based platform, and clinical pipeline in neuroendocrine tumors, melanoma, and other solid tumors, with Phase 1/2 data expected in 2026.

What is the core technology highlighted by Perspective Therapeutics (CATX)?

The company emphasizes a proprietary radioligand platform built around the alpha-emitting isotope lead-212 (212Pb). It describes a Pb-based chelator designed for broader and safer use, aiming to optimize therapeutic index and improve targeted delivery of radiotherapy to solid tumors in oncology.

Which cancer programs are featured in Perspective Therapeutics’ updated presentation?

The presentation highlights VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 targeting MC1R in melanoma, and PSV359 targeting FAP-α in advanced solid tumors. All three are in Phase 1/2a open-label trials, with early anti-tumor activity and safety supporting continued development.

When does Perspective Therapeutics (CATX) expect key clinical data from its programs?

The company states that Phase 1/2 data are expected across all three clinical programs in 2026. These include VMT-α-NET in neuroendocrine tumors, VMT01 in melanoma, and PSV359 in advanced solid tumors, reflecting its focus on solid tumor radiopharmaceutical therapies.

How does Perspective Therapeutics describe safety and activity for VMT-α-NET and VMT01?

The presentation notes a best-in-class safety profile for VMT-α-NET with durable disease control and sustained responses. For VMT01 in melanoma, it reports that treatment is well-tolerated with preliminary anti-tumor activity at lower doses, supporting further clinical development in ongoing Phase 1/2a trials.

What manufacturing capabilities does Perspective Therapeutics highlight in the presentation?

Perspective Therapeutics describes end-to-end manufacturing with clinical supply secured and commercial scale underway. It notes daily production at regional sites to ensure supply of ready-to-administer radiopharmaceutical product, supporting its 212Pb-based oncology portfolio and ongoing clinical trials.

Filing Exhibits & Attachments

2 documents

Press Releases

EX-99.1 EX-99.1 18.4 KB